REDSENSE ALARM SYSTEM

{0}------------------------------------------------ # NOV 222 2013 # 2. 510(k) Summary #### Submitter: Redsense Medical AB · Gyllenhammars väg 26 302 92 HALMSTAD SWEDEN # Contact Information: Mr.PatrikByhmer Patrik.byhmer@redesensemedical.com # Submission Date: February 28, 2013 Device Name/trade name and Classification: Redsense alarm system, Class II, 21 CFR 876.5820 and product code ODX ## Equivalent Device Identification: | Comments of the control of the control of the first of the first of the contribution of the comments of the comments of the comments of the comments of the comments of the co<br>Redsense Medical alarm unit K103242 | | |-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--| | Redsense Medical home use K092955 | | Device Description: Redsense Medical provides a system for monitoring the blood access during haemodialysis consisting of an alarm unit and a sensor connected to a specifically developed patch. The Redsense Patch uses integrated optic fibers to detect blood leakage from wounds. The optic fiber is connected to the sensor and alarm unit. If blood leakage occurs during haemodialysis, the patch surrounding the vein needle registers the event and changes a light signal to the alarm unit. This immediately activates a light and an alarm signal. Thus if a vein needle comes out of place extensive blood leakage is prevented. ## Intended Use: The Redsense device is intended to monitor for potential blood loss from the hemodialysis access site in hemodialysis patients undergoing hemodialysis treatment. The device includes a blood sensor incorporated into a sensor patch. The sensor monitors potential blood leakage from the venous needle blood access via a light signal and will alarm if blood leakage is detected by the device's sensor. #### Issue 19Nov2013 {1}------------------------------------------------ # Comparison Table | | Redsense alarm system | Redsense alarm unit | Redsense home use | |---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Used | Home/self+ clinic | Clinic | Home/self | | Usage time | NA ( not battery operated) | 8h | 5h | | 510(k) number | New (k130554) | K103242 | K092955 | | Intended use | The Redsense device is intended to monitor for potential blood loss from the hemodialysis access site in hemodialysis patients undergoing hemodialysis treatment. The device includes a blood sensor incorporated into a sensor patch. The sensor monitors potential blood leakage from the venous needle blood access via a light signal and will alarm if blood leakage is detected by the device's sensor. | The Redsense device is intended to monitor for potential blood loss from the hemodialysis access site in hemodialysis patients undergoing continuous hemodialysis treatment up to 8 hours in the clinical settings. The device includes a blood sensor incorporated into an adhesive sensor patch. The sensor monitors potential blood leakage from the venous needle puncture site via an infrared light and will alarm if blood leakage is detected via absorption onto the device's sensor patch. | The Redsense device is intended to monitor for potential blood loss from the hemodialysis access site in hemodialysis patients undergoing hemodialysis treatment up to 5 hours at home or in the clinical setting. The device includes a blood sensor incorporated into an adhesive dressing. The sensor monitors potential blood leakage from the needle puncture via an infrared light and will alarm if needle dislodgement or blood leakage is detected.<br>All use must be administrated under physician's prescription, and must be observed by a trained and qualified person considered to be competent in the use of this device by the prescribing physician. | | Manufacturer | Audible Alarm<br>Redsense Medical<br>Complying with IEC<br>60 601-2-16 51,107; | Redsense Medical<br>Complying with IEC<br>60 601-2-16 51,107; | Redsense Medical<br>Complying with IEC<br>60 601-2-16 51,107; | Issue 19Nov2013 {2}------------------------------------------------ | | Requirements=<br>65dB(A) at 1 m<br><br>Sound test report = 72<br>dB(A) at 1m | Requirements=<br>65dB(A) at 1 m<br><br>Sound test report = 72<br>dB(A) at 1m | Requirements=<br>65dB(A) at 1 m<br><br>Sound test report = 72<br>dB(A) at 1m | |------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------| | Operation power | Power supply | Internal rechargeable<br>battery | Internal rechargeable<br>battery | | EMC requirements | Fulfills IEC 60601-1-<br>2:2001 and IEC 61000-<br>6-1 (for Medical<br>devices + home use) | Fulfills IEC 60601-1-<br>2:2001 and IEC 61000-<br>6-1 (for Medical devices<br>+ home use) | Fulfills IEC 60601-1-<br>2:2001 and IEC 61000-<br>6-1 (for Medical<br>devices + home use) | | Type of Clinical trial<br>obtained | No new clinical data.<br>Same as K071013<br>used. | No new clinical data.<br>Same as K071013 used. | No new clinical data.<br>Same as K071013<br>used. | | Electrical contact | Standard US electrical<br>outlet (power supply) | Standard US electrical<br>outlet (charger) | Standard US electrical<br>outlet (charger) | | Sensor used | New Redsense sensor | Redsense Sensor | Redsense Sensor | # Discussion with respect to predicate devices The Redsense alarm system is not battery operated, has two material changes (skin contact material), the sensor is slightly re-designed and can be used both at the clinic and at home. There is one predicate device k071013 manufactured by Redsense Medical as well not part of the table above but is also very similar in the technique and material. The predicate devices above rely on the clinical user evaluation data for the k071013 as well as some of the materials and so does the new device. The new sensor operates on the same optical principle but is designed differently to be automate the production. This will reduce operator introduced risks as well as provide a better more stable production process. Instead of a bend of a thinner optical fiber we use a thicker which has been processed with a tip that will cause the same physical phenomena as with a bend of the fiber. The redesign of the patch is that we use two materials that are flexible thus casier to place over a fistula that bulges. Also we use a larger absorbent patch so that the placement of the sensor becomes more forgiving. All devices refer to the same clinical evidence presented in K071013. The changes we have made for the subject device are driven mainly by user feed-back. The clinical evaluations we have made is to confirm that the users can handle the device and understand it use. The ability to detect blood is validated in nonclinical test. The major reason for change in the software is due to the change in power management. The predicate device was driven from a rechargeable battery. The subject device is not battery driven but instead supplied continuously from the power socket. For example the alarm algorithm for detecting blood is the same as is the failure handling in the software (i.e. low power, faulty signals etc). # Summary of Testing: Verification testing has been performed to verify that the Redsense Alarm system device fulfills the Requirement Specifications. The electrical safety and EMC are fulfilled as well as the biocompatibility of the material and the performance. {3}------------------------------------------------ Conclusion: Redsense Alarm system is similar in function and intended use to the Redsense Medical k071013, Redsense Alarm unit k103242 and home use device k092955. Verification and user evaluation show the Redsense systems to be safe and effective for the intended use. - - - ・ ## Issue 19Nov2013 Issue 19Nov2013 : {4}------------------------------------------------ Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized symbol resembling a human figure with outstretched arms, accompanied by the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged in a circular fashion around the symbol. The text is in all capital letters and is positioned to encircle the symbol. Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring MD 20993-00002 November 22, 2013 Redsense Medical AB Patrik Byhmer CEO Gyllenhammars väg 26 Halmstad 30292 Sweden Re: K130554 > Trade/Device Name: Redsense Alarm System Regulation Number: 21 CFR§ 876.5820 Regulation Name: Hemodialysis system and accessories Regulatory Class: II Product Code: ODX Dated: October 14, 2013 Received: October 17, 2013 Dear Patrik Byhmer, We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. {5}------------------------------------------------ Page 2 - Patrik Byhmer You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH0ffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Sincerely yours. # Herbert P., Lerner -S for Benjamin R. Fisher. Ph.D. Director Division of Reproductive, Gastro-Renal, and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {6}------------------------------------------------ ## DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use 610(k) Number (If known) K 130554 Device Name Redsense Alam System Indications for Use (Describe) The Redserse device is intended to potential blood loss from the hemodialysis access site in hemodialysis patients undergoing hemodlalysis treatment. The device indudes a blood sensor incorporated into a sensor monitors potential blood leakege from the versous needle blood access via a light signal and will alam if blood leakage is detected by the device's sensor. Type of Use (Select one or both, as applicable) Prescription Use (Part 21 CFR 801 Subpart D) [] Over-The-Counter Use (21 CFR 801 Subpart C) PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED. SEAST PROPERTY CONTRACT FOR FOR FOR FOR FOR FOR FOR FOR FOR FOR FOR FOR FOR FOR FOR FOR FOR FOR Concurrence of Canter for Devices and Radiological Health (CDRH) (Signature) Herbert P. Lemer - 5 2013.11.22 17:04:50:-05'00' FORM FDA 3881 (8/13) Page 1 of 2 75C Publishing Serion (101) 410-4700 Form Approved: OMB No. 0910-0120 Expiration Date: December 31, 2013 See PRA Statement on last page.